Advanced Solid Tumors Clinical Trials in Philadelphia, Pennsylvania

5 studies are recruiting for advanced solid tumors in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

   The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   22 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT06795412 on ClinicalTrials.gov

2. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

3. A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

   To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Pennsylvania, Philadelphia, Pennsylvania

   Locations

   39 in total

   Run by

   Incyte Corporation

   See if you can join NCT05836324 on ClinicalTrials.gov

4. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

   The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fox Chase Cancer Center, Philadelphia, Pennsylvania

   Locations

   7 in total

   Run by

   Tagworks Pharmaceuticals BV

   See if you can join NCT06959706 on ClinicalTrials.gov

5. SNV4818 in Participants With Advanced Solid Tumors

   This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Thomas Jefferson University-Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania

   Locations

   12 in total

   Run by

   Pikavation Therapeutics, Inc.

   See if you can join NCT06736704 on ClinicalTrials.gov